Literature DB >> 3143223

Growth hormone secretion and response to growth hormone therapy after treatment for brain tumour.

B Lannering1, I Marky, L Mellander, K Albertsson-Wikland.   

Abstract

Children irradiated for brain tumours constitute an increasing group of patients who will require GH therapy. High-dose cranial irradiation is necessary for cure, but inevitably causes GH deficiency within a few years. In 19 patients investigated between 2 and 9 years after irradiation, the spontaneous 24-hour GH secretion was markedly reduced. The secretory pattern indicated loss of regulating hypothalamic hormones. After exogenous GHRH was administered, the pituitary was able to respond with a prompt GH release, showing that pituitary function was unaffected. Ten prepubertal children growing at 3.8 +/- 0.3 cm/year were treated with GH, 0.1 IU/kg/day s.c. Their growth rate increased to 8.2 +/- 0.4 cm in the first year. An increased growth rate was also maintained in the second year.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3143223     DOI: 10.1111/j.1651-2227.1988.tb10815.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand Suppl        ISSN: 0300-8843


  4 in total

1.  Regarding some aspects of the positive and negative effects of ionizing and medical treatment of pediatric brain tumors.

Authors:  P Iannetti; L A Basile; L Chessa
Journal:  Childs Nerv Syst       Date:  1992-10       Impact factor: 1.475

2.  Growth hormone treatment of growth failure secondary to total body irradiation and bone marrow transplantation.

Authors:  A Papadimitriou; M Urena; G Hamill; R Stanhope; A D Leiper
Journal:  Arch Dis Child       Date:  1991-06       Impact factor: 3.791

3.  Polygraphic sleep patterns and growth hormone secretion in children after cranial irradiation.

Authors:  I Fagioli; R Brauner; R Rappaport
Journal:  Eur J Pediatr       Date:  1991-01       Impact factor: 3.183

4.  Late endocrine sequelae after radiotherapy of pediatric brain tumors are independent of tumor location.

Authors:  T R Rohrer; J D Beck; G G Grabenbauer; R Fahlbusch; M Buchfelder; H G Dörr
Journal:  J Endocrinol Invest       Date:  2009-04       Impact factor: 4.256

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.